证券代码：301258 证券简称：富士莱 公告编号：2025-053 苏州富士莱医药股份有限公司 关于使用自有资金回购公司股份方案的公告 5、回购股份的实施期限：自公司董事会审议通过本次回购方案之日起 12 个月内。 6、回购股份的资金总额：不低于人民币 2,000 万元（含本数）且不超过人 民币 4,000 万元（含本数），具体回购资金总额以实际使用的资金总额为准。 7、回购股份的资金来源：公司自有资金。 8、拟回购的方式：通过深圳证券交易所交易系统以集中竞价交易的方式回 购公司股份。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 重要内容提示： 1、回购股份的种类：苏州富士莱医药股份有限公司（以下简称"公司"或 "富士莱"）已在境内发行上市的人民币普通股（A 股）股票。 2、回购股份的用途：将在未来适宜时机用于实施股权激励计划或员工持股 计划。若公司未能在本次股份回购实施结果暨股份变动公告日后三年内使用完毕 已回购股份，尚未使用的已回购股份将依法予以注销。如国家对相关政策做调整， 则按调整后的政策执行。 3、回购股份的价格：不超过人民币 40.00 元/股 ...

证券代码：301258 证券简称：富士莱 公告编号：2025-052 苏州富士莱医药股份有限公司 第五届董事会第二次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 苏州富士莱医药股份有限公司（以下简称"公司"）第五届董事会第二次会议 于 2025 年 10 月 13 日上午 10 时在公司会议室以通讯表决方式召开，会议通知于 2025 年 10 月 11 日以邮件、电话、书面等方式通知全体董事。经全体董事一致 同意，本次会议豁免通知时限要求。本次会议应出席董事 7 人，实际出席董事 7 人。本次会议由董事长钱祥云先生召集并主持，公司高级管理人员列席了本次会 议。会议的召集、召开及表决程序符合法律法规及《公司章程》的有关规定。 一、议案审议情况 与会董事经过审议，以记名投票表决方式通过如下决议： （一）审议通过《关于使用自有资金回购公司股份方案的议案》 同意公司使用自有资金不低于人民币 2,000 万元（含本数）且不超过人民币 4,000 万元（含本数）通过集中竞价交易方式回购公司普通股（A 股）股票，在 未来适宜时机用于股权激励计划或员工持股计划。 ...

Core Points - On September 29, a total of 25 listed companies had their restricted shares unlocked, with a total market value of approximately 24.818 billion yuan [1] Summary by Category Restricted Share Unlocking - The companies involved in the unlocking of restricted shares include: - Luzhou Laojiao (000568) with 102,700 shares from equity incentive restrictions - East China Pharmaceutical (000963) with 215,000 shares from equity incentive restrictions - Taiyuan Heavy Industry (600169) with 11.6502 million shares from equity incentive restrictions - Jinfat Technology (600143) with 7.406 million shares from equity incentive restrictions - Guotai Junan (601211) with 3.2495 million shares from equity incentive restrictions - Guanglian Da (002410) with 3.2334 million shares from equity incentive restrictions - Ningbo Port (601018) with 3.647 billion shares from A-share issuance to legal person allocation - Zhongjin Environment (300145) with 852,070 shares from equity incentive restrictions - Keli Ke (002782) with 768,000 shares from equity incentive restrictions - Yingjie Electric (300820) with 62,500 shares from equity incentive restrictions - Laobaixing (603883) with 868,400 shares from equity incentive restrictions - Zhaoxun Media (301102) with 218 million shares from extended lock-up period - Zhongjing Technology (003026) with 20,000 shares from equity incentive restrictions - Woge Optoelectronics (603773) with 14.8003 million shares from A-share issuance to original shareholders allocation - Hanrui Cobalt (300618) with 104,670 shares from equity incentive restrictions - Fujilai (301258) with 55.362 million shares from extended lock-up period - Wankai New Materials (301216) with 225 million shares from extended lock-up period - Weiteou (301319) with 29.8 million shares from pre-issue share restrictions - Guanshi Technology (605588) with 19,870 shares from equity incentive restrictions - Sanwang Communication (688618) with 13,500 shares - Xidi Micro (688173) with 771,800 shares - Rendu Biology (688193) with 8.4316 million shares - Jinchang Protein (688137) with 7.145 million shares - Jiao Cheng Ultrasound (688392) with 43.8612 million shares - Aike Saibo (688719) with 824,800 shares [1]

Group 1 - On September 29, a total of 19 companies had their restricted shares unlocked, with a total unlock volume of 4.644 billion shares, equating to a market value of 32.275 billion yuan based on the latest closing price [1] - Nine companies had unlock volumes exceeding 10 million shares, with Ningbo Port, Zhaoxun Media, and Deep Expressway leading in unlock volume at 3.647 billion shares, 304 million shares, and 281 million shares respectively [1] - In terms of unlock market value, nine companies had unlock values exceeding 100 million yuan, with Ningbo Port, Wankai New Materials, and Jiao Cheng Ultrasonic leading at 13.202 billion yuan, 4.665 billion yuan, and 4.374 billion yuan respectively [1] Group 2 - Six companies had an unlock ratio exceeding 10% of their total share capital, with Zhaoxun Media, Fujilai, and Wankai New Materials having the highest unlock ratios at 75.0%, 60.26%, and 40.9% respectively [1]

Group 1 - A total of 36 stocks will face unlock restrictions in the next two trading days before the National Day holiday, with a combined unlock market value of 40.081 billion yuan [1] - Ningbo Port will have 3.647 billion shares listed for circulation, primarily from the allocation of shares to targeted placement institutions, with an unlock market value of 13.202 billion yuan [1] - Wankai New Materials will have 230 million shares listed for circulation, mainly from the original shareholders' restricted shares, with an unlock market value of 4.665 billion yuan [1] Group 2 - The companies with the highest unlock ratios include Zhaoxun Media, Bofei Electric, Fujilai, and Oujing Technology, all exceeding 50% [2]

Group 1 - Fujilai's stock price increased by 0.24% on September 25, with a trading volume of 43.61 million yuan. The margin trading data shows a financing purchase amount of 3.72 million yuan and a net financing purchase of 159,200 yuan for the day [1] - As of September 25, the total margin trading balance for Fujilai is 74.99 million yuan, accounting for 6.10% of its market capitalization, indicating a high level compared to the past year [1] - Fujilai's main business includes the research, production, and sales of active pharmaceutical ingredients and health product raw materials, with revenue contributions from various product lines: 66.02% from alpha-lipoic acid series, 14.86% from carnosine series, 11.88% from etoricoxib, and 5.95% from phosphatidylcholine series [1] Group 2 - As of September 19, Fujilai has 11,000 shareholders, a decrease of 4.22% from the previous period, while the average circulating shares per person increased by 4.40% to 3,088 shares [2] - For the first half of 2025, Fujilai reported a revenue of 224 million yuan, a year-on-year increase of 3.36%, and a net profit attributable to shareholders of 43.08 million yuan, a significant year-on-year increase of 12,430.96% [2] - Fujilai has distributed a total of 153 million yuan in dividends since its A-share listing, with 116 million yuan distributed over the past three years [3]

证券日报网讯9月24日晚间，富士莱（301258）发布关于部分首次公开发行前已发行股份上市流通的提 示性公告称，本次解除限售的股份为公司部分首次公开发行前已发行限售股，本次解除限售股东户数共 计2户，解除限售股份的数量为55，362，000股，占公司目前总股本的60.3927%，限售期为自公司首次 公开发行并上市之日起42个月。本次解除限售的股份上市流通日期为2025年9月29日(星期一)。 ...

证券代码：301258 证券简称：富士莱 公告编号：2025-051 苏州富士莱医药股份有限公司 关于部分首次公开发行前已发行股份上市流通的 提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 特别提示： 1、本次解除限售的股份为苏州富士莱医药股份有限公司（以下简称"公司"、 "发行人"或"富士莱"）部分首次公开发行前已发行限售股。 2、本次解除限售股东户数共计 2 户，解除限售股份的数量为 55,362,000 股， 占公司目前总股本的 60.3927%，限售期为自公司首次公开发行并上市之日起 42 个月。 3、本次解除限售的股份上市流通日期为 2025 年 9 月 29 日（星期一）。 一、首次公开发行前已发行股份概况 （一）首次公开发行股票情况 经中国证券监督管理委员会《关于同意苏州富士莱医药股份有限公司首次公 开发行股票注册的批复》（证监许可〔2022〕251 号）同意注册，公司首次公开 向社会公众发行人民币普通股（A 股）股票 2,292 万股，并于 2022 年 3 月 29 日 在深圳证券交易所创业板上市。 2023 年 10 月 09 日 ...

东方证券股份有限公司 关于苏州富士莱医药股份有限公司 部分首次公开发行前已发行股份上市流通的核查意见 东方证券股份有限公司（以下简称"东方证券"或"保荐机构"）作为苏州 富士莱医药股份有限公司（以下简称"富士莱"或"公司"）首次公开发行股票 并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等法律法规的有关规定，对富士莱本次部分首次公开发行前已 发行股份上市流通的事项进行了审慎核查，具体情况如下： 一、公司首次公开发行股票的情况 （一）首次公开发行股票情况 经中国证券监督管理委员会《关于同意苏州富士莱医药股份有限公司首次公 开发行股票注册的批复》（证监许可〔2022〕251号）同意注册，公司首次公开 向社会公众发行人民币普通股（A股）股票2,292万股，每股面值人民币1.00元， 每股发行价格为48.30元。公司总股本由6,875.00万股变更为9,167.00万股，其中 有限售条件的股份数量为69,934,117股，占公司总 ...

Group 1 - The stock price of Fujilai (301258.SZ) decreased by 4.35%, closing at 34.29 yuan [1] - Fujilai was listed on the Shenzhen Stock Exchange's ChiNext board on March 29, 2022, with an issuance of 22.92 million shares at a price of 48.30 yuan per share [1] - The stock reached its highest price of 80.39 yuan on its first trading day, but is currently in a state of decline [1] Group 2 - The total amount raised from the initial public offering (IPO) was 1.107 billion yuan, with a net amount of 1.003 billion yuan after deducting issuance costs [1] - The net amount raised exceeded the original plan by 333 million yuan [1] - The IPO expenses totaled 104 million yuan, with underwriting and sponsorship fees amounting to approximately 78.8 million yuan [1] Group 3 - The funds raised are intended for projects including the expansion of production capacity for 720 tons of pharmaceutical intermediates and raw materials, a research and development center, information technology construction, and to supplement working capital [1]